Daily non-political popular news in brief.

A simple new way to predict advanced fibrosis in patients with nonalcoholic fatty liver disease

Certain routine demographic, clinical, and laboratory values can be used to identify advanced fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). This method could render liver biopsy unnecessary in a large proportion of patients.

Read more »

Keywords: simple, way, predict, advanced, fibrosis, patients, nonalcoholic, fatty, liver, disease, fibrosi, patient

« Previous | Next »

Similar news on "A simple new way to predict advanced fibrosis in patients with nonalcoholic fatty liver disease":

1. Geisinger launches extensive study on obesity and related liver problem
   04-16-2007 · EurekAlert!
   Geisinger Health System researchers in Danville, Pa., are looking at the genetics of obesity through a unique study. Geisinger patients have voluntarily donated more than 600 liver tissue samples so that researchers can study obesity and also develop a safer, noninvasive way of detecting an obesity-related condition: nonalcoholic fatty liver disease. Relying on several core system resources in the study, Geisinger researchers hope to know more about nonalcoholic fatty liver disease and related health problems.
   Similar news · Read more »
   
2. New sepsis model may help shape patient care
   06-13-2007 · EurekAlert!
   A new mathematical model of sepsis can help predict deaths, discharges and disease progression in hospital patients with this serious bacterial blood infection. It's hoped the model, described in the online open access journal Critical Care, will help clinicians assess which interventions are likely to be best for their patients.
   Similar news · Read more »
   
3. Experts predict high mortality rates from pulmonary fibrosis will continue to rise
   08-01-2007 · EurekAlert!
   Mortality rates from pulmonary fibrosis have increased significantly in recent years, and are predicted to continue to rise, according to researchers from the University of Colorado. Between 1992 and 2003, the age-adjusted mortality rate from PF -- an often fatal disease which involves scarring of the lung -- rose by nearly 28.4 percent in men, and 41.3 percent in women. Over the same time period, an increasing percentage of patients with PF died of the disease itself rather than of coexisting conditions.
   Similar news · Read more »
   
4. Researchers show that fibrosis can be stopped, cured and reversed
   12-26-2007 · EurekAlert!
   University of California, San Diego researchers have proven in animal studies that fibrosis in the liver can be not only stopped, but reversed. Their discovery, to be published in PLoS Online on Dec. 26, opens the door to treating and curing conditions that lead to excessive tissue scarring such as viral hepatitis, fatty liver disease, cirrhosis, pulmonary fibrosis, scleroderma and burns.
   Similar news · Read more »
   
5. Genetic marker linked to aggressive prostate cancer
   05-20-2007 · EurekAlert!
   Northwestern University researchers have discovered that a recently identified genetic marker for prostate cancer is linked to a highly aggressive form of the disease. These findings ultimately will aid the development of a simple blood test to predict who is susceptible to this aggressive cancer. Knowing which patients carry this genetic marker also will guide doctors in how they treat the cancer. The study showed a strong hereditary component to this aggressive cancer.
   Similar news · Read more »
   
6. Molecules may help predict survival in liver cancer
   01-30-2008 · EurekAlert!
   Tiny molecules that help cells regulate which proteins they make might one day help doctors predict which liver-cancer patients are likely to live longer than others. Researchers compared levels of microRNA in tumor cells and adjacent nontumor cells from liver-cancer patients, most of whom also had hepatitis and cirrhosis. Patients with poor disease-free survival had low overall levels of 19 particular microRNAs compared with those showing better survival after 16 years of follow-up.
   Similar news · Read more »
   
7. Interferon does not slow or stop hepatitis C from worsening, study finds
   11-08-2007 · EurekAlert!
   Interferon does not slow or halt the progression of chronic hepatitis C and advanced liver disease in patients who haven't responded to previous attempts to eradicate the disease, a national study has found. Patients who were treated with interferon did experience a significant decrease in viral levels and liver inflammation, but the trial unequivocally demonstrated that treatment with interferon does not prevent the worsening of liver disease in patients who've failed prior treatments.
   Similar news · Read more »
   
8. New research may lead to earlier diagnosis and treatment of primary biliary cirrhosis in families
   09-10-2007 · EurekAlert!
   Mayo Clinic researchers have found that first-degree relatives (i.e., parents, siblings, children) of patients with primary biliary cirrhosis are more likely to have the biomarker of the disease in their blood. Armed with this new information, physicians could screen and assess first-degree relatives of PBC patients with a simple blood test, enabling them to diagnose and treat more patients before the disease causes irreversible liver damage. These findings were published in this month's issue of Hepatology.
   Similar news · Read more »
   
9. Omega-3 Fatty Acids May Slow Cognitive Decline In Some Patients With Very Mild Alzheimer's Disease
   10-11-2006 · ScienceDaily
   Omega-3 fatty acid supplements may slow cognitive decline in some patients with very mild Alzheimer's disease, but do not appear to affect those with more advanced cases, according to results of a clinical trial published in the October issue of Archives of Neurology, one of the JAMA/Archives journals.
   Similar news · Read more »
   
10. New type of drug shows promise in attacking melanoma in an innovative way
    09-26-2007 · EurekAlert!
    An experimental drug that attacks cancer in an entirely new way has shown promise in treating advanced melanoma, delaying progression of the disease and prolonging the lives of patients. New research presented today at the European Cancer Conference in Barcelona found that giving the new drug in addition to chemotherapy more than doubled the amount of time patients survived without progression of their cancer.
    Similar news · Read more »